Navigation Links
Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
Date:4/10/2008

ther platinum therapies."

ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access is currently in the process of planning additional ProLindac clinical trials that will include combination therapy trials in one or more solid tumor types.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve cli
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. New Legislation Would Expedite Medicare Patient Access to Physical Therapy
2. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
3. Medicare Advantage Plans Have New, Better Way to Access CMS Data
4. Stryker to Provide Webcast and Telephone Access to Annual Shareholder Meeting
5. Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
6. Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide
7. Toms of Maine Helps Increase Access to Dental Care
8. Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress
9. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
10. Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured
11. Country Music Star Troy Gentry Partners With National Non-Profit Patient Advocate Foundation to Spread the Message About Challenges to Healthcare Access for Insured and Uninsured Americans

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBart...on,slargestmedicalcliniconDec.9-10,whenKansasCityh...uredpeople. ,, "Thisfreecliniceventhasthepotent...daysinsteadofjustoneandbeheldonweekdaysinsteadofov...CityFreeHealthClinicandpresidentoftheNationalAssoc...
(Date:11/25/2009)...,, TORONTO,Nov.25/PRNewswire/-SentinelleMedic...ncedvisualizationsoftwarelaunchesasuiteofnewleadin...ingsoftwareplatformatthisyear,sRadiologicalSociety...Dec.5,2009(Booth5800,HallA).Theapplicationsleverag...specializedMRIimagingcoilsandsupportmultipleimagin...
(Date:11/25/2009)...,, LOSANGELES,Nov.25/PRNewswire-USNewswire/--...ectionstodetermineexecutiveleadershipfor2010. ,...swithspecialtiesinpublicpolicy,law,finance,governm...rship.TheBoardalsocomesfromawiderangeofpersonalbac...women,somelivingwithHIVthemselves,andrepresentingm...
(Date:11/25/2009)... Long-term survivors of testicular cancer who wer...re severe side effects, including neurological sid... were not treated with chemotherapy, according to ...ournal of the National Cancer Institute . , Mari...aukeland University Hospital, in Bergen, Norway, a...
(Date:11/25/2009)... Does stress increase blood pressure? This simpl...for many years. New Stress-related gene Modulates...ncrease blood pressure? This simple question has ... Now new research has for the first time establis...e blood pressure response to stress in mice as wel...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
...J Officials, Legal Experts to Discuss Latest Crimi...and Dietary Supplement,Industries, WASHINGTON, De... companies have agreed to pay more than $1.9,billi...or know about the crimes., With the Federal Gover...
...ugh the new Agri-Opportunities program of Agricult...) -, BELLEVILLE, ON, Dec. 20 /PRNewswire-FirstCal...earch-based, technology-driven Canadian,biopharmac...p in Belleville, Ontario. The $5 million repayable...
...a, PA, December 20, 2007 For U.S. veterans with d...unctioning are associated with an increased risk o...er/December issue of the journal General Hospital ...appropriate interventions to counteract this highe...
.... and CHARLESTON, S.C., Dec. 20 LTC,Financial Par...e insurance,brokerage, has more than quadrupled in...ers and support staff. That just one sign of what,...pg), *(Photo Caption: LTC Financial CEO Cameron T...
...lapharma.com Toronto Stock Exchange Symbol: AKL, ...Pharma Inc. (TSX:,"AKL"), a drug development compa...ion and pain markets, today announced that due to ...y is currently,contemplating other financing optio...
...team led by Dr. Paul Wiseman of the Departments of...veloped a radically new technique that uses lasers...infection in human blood, according to a study pub...of the malaria parasite in blood samples. , Malar...
Other Medicine News:Health News:Food and Drug Law Institute Sponsors Major Enforcement Conference 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5Health News:Mental health linked to amputation risk in diabetic veterans 2Health News:The Long Term Care Insurance Explosion; January Conference to Celebrate Rapid Growth of LTC Protection and Light Fuse of Further Expansion 2Health News:Akela Pharma provides corporate update 2Health News:McGill researchers report breakthrough in rapid malaria detection 2
(Date:11/25/2009)...,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,announced...OTECT-1(theProspectiveRandomizedOralTherapyEvaluat...B)inpatientswithmoderate-to-severeCrohn,sdiseasede...olerabilityprofile.Thestudydemonstratedevidenceofc...finedasa70-pointdecreaseintheCrohn,sDiseaseActivit...
(Date:11/24/2009)...4/PRNewswire-FirstCall/--Endologix,Inc.(Nasdaq: EL...icdisorders,announcedtodaythatithasfiledamotiontos...ementlawsuitbroughtagainstitinOctober2009byCook,In...nIndianapolis,Indiana. ,, Endologixhasrequested...tandTrademarkOffice(USPTO)conductsproceedingstore-...
(Date:11/24/2009)...ewswire-FirstCall/--AnadysPharmaceuticals,Inc.(Nas...tAnnualPiperJaffrayHealthcareConferenceonTuesday,D...nceisbeingheldatTheNewYorkPalaceHotel.SteveWorland...illprovideanoverviewofAnadysanditsclinicaldevelopm...sentationwillbesimultaneouslywebcastandcanbeaccess...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 1Do Good When You Shop and Help Educate a Generation of Healthy Kids 55736 2Is Eye Exam on Your Back to School List 3F 55735 1Is Eye Exam on Your Back to School List 3F 55735 2Study reveals how a common virus eludes the immune system 55733 1
...lts from Exploratory Phase IIa Clinical Trial in T...8, 2007 /PRNewswire-FirstCall/ - Transition,Therap...esults from,its exploratory Phase IIa clinical tri...h gastrin-based therapy, E1-I.N.T.(TM), showed,sus...ers, including,haemoglobinA1C (HbA1c), for 6 month...
...ON, June 28, 2007 /PRNewswire/ - Cytochroma Inc.,a...al trial of,CTA018 Injection. The initial top-line...fe and well tolerated. Complete study,results are ...Phase I trial was an open label,placebo-controlle...ed to 20 healthy volunteers. In this trial, the sa...
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3
ExcaliburPlus PC, 100V, 50Hz/60Hz
ExcaliburPlus PC, 220V, 50Hz
Bipolar Coagulator
Elmed BC 50 M/M
Medicine Products: